رناد زكريا Dr. ahmad Dr. ahmad. P a g e 1

Similar documents
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease

Myelodysplastic Syndromes Myeloproliferative Disorders

Polycthemia Vera (Rubra)

Dana Alsulaibi. - Ahmad Almuhtaseb. - Tariq Al - Adaily

CLINICAL CASE PRESENTATION

Chronic Myeloproliferative Disorders

Polycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi

4 Jumana Jihad Dr. Ahmad Mansour Dr. Ahmad Mansour

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Chronic Idiopathic Myelofibrosis (CIMF)

WHO Update to Myeloproliferative Neoplasms

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

Bone Marrow Transplantation

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

بسم هللا الرحمن الرحيم

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Hemolytic anemias (2 of 2)

Department of Clinical Haematology

2013 Pathology Student

Done by :Aseel Twaijer & Laith Sorour Hemolytic Anemias

Theme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects -

POLYCYTHEMIA VERA (PV)

Paroxysmal Nocturnal Hemoglobinuria

Heme 9 Myeloid neoplasms

RBCs Disorders 2. Dr. Nabila Hamdi MD, PhD

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms

Hemoglobin and anemia BCH 471

The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011)

Lec.2 Medical Physiology Blood Physiology Z.H.Kamil

THE UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PATHOLOGY HEMOLYTIC ANEMIAS. Dr. Tariq Aladily

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

MYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).

Emerging diagnostic and risk stratification criteria

THE UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PATHOLOGY

Anemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi

QUESTIONS OF HEMATOLOGY AND THEIR ANSWERS

Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination

Glucose-6-Phosphate Dehydrogenase

DONE BY : RaSHA RAKAN & Bushra Saleem

SESSION 1 Reactive cytopenia and dysplasia

MYELOPROLIFERATIVE NEOPLASMS

Zeina Al-Assaf. Mustafa Khader. Nayef Karadsheh

Myeloproliferative Neoplasms and Treatment Overview

RBCs Disorders 2. Dr. Nabila Hamdi MD, PhD

PNH Glossary of Terms

MPL W515L K mutation

Anemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017

Approach to Hemolysis

YEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY

Why do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012

Examination Tests from Pathological Physiology. Pavel Maruna et al. Reviewed by: Prof. MUDr. Emanuel Nečas, DrSc. Prof. MUDr. Jaroslav Veselý, CSc.

COEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE?

Around million aged erythrocytes/hour are broken down.

Anemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh

Characterization of blood donors with high haemoglobin concentration

Index. Note: Page numbers of article titles are in boldface type.

Extra Notes 3. Warm. In the core (center) of the body, where the temperature is 37 C.

Year 2003 Paper two: Questions supplied by Tricia

General Characterisctics

Polycythemia Vera and Essential Thombocythemia A Single Institution Experience

3 Ruba hussein Dr. ahmad Dr. ahmad

Technical Bulletin No. 100

20/01/1439. Prof. M. Rushdi. Prof. Mahmoud Rushdi Faculty of Veterinary Medicine Assiut University Egypt.

A. Blood is considered connective tissue. RBC. A. Blood volume and composition 1. Volume varies - average adult has 5 liters

Increased Number of Red Blood Cells (Polycythemia) Basics

C. treatment with Desferal (deferoxamine mesylate USP, iron-chelating agent)

SICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

WHICH OF THE FOLLOWING COMPRISE A

SYLLABUS ON HEMATOLOGY FOR THE 4-YEAR STUDENTS, MEDICINE-2. Total hours number 70 hours, including course 20 hours, seminars 50 hours.

10/27/2017 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DANIEL LANDAU, MD PNH TYPICAL CASE

Dairion Gatot, Soegiarto Ganie, Savita Handayani. Divisi Hematologi & Onkologi Medik Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik Medan 2009

Hemoglobinopathies Diagnosis and management

Disorders of Blood Cells & Blood Coagulation

JAK2 V617F analysis. Indication: monitoring of therapy

HEMOLYTIC ANEMIA Anemia of increased destruction Normochromic, normochromic anemia Shortened RBC survival Reticulocytosis - Response to increased RBC

Average adult = 8-10 pints of blood. Functions:

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Tim R. Randolph. PhD, MT(ASCP) Chair and Associate Professor Department of Biomedical Laboratory Science Saint Louis University

Bone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany

Latest updates in Myeloproliferative Neoplasms. Elizabeth Hexner, MD, MSTR

Composition of Blood

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:

HAEMOLYTIC ANAEMIA. Dr. Hasan Fahmawi, MRCP(London), FRCP(Edin) Consultant Physician

Case Presentation No. 075

HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).

[COMPREHENSIVE GENETIC ASSAY PANEL ON

UNDERSTANDING POLYCYTHEMIA VERA (PV) A guide for patients and caregivers

PNH. PNH A study case 5/9/2012. PNH Current Thinking on the Disease, Diagnosis, and Treatment. Where have we been, where are we going?

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration

Year 2004 Paper two: Questions supplied by Megan 1

Transcription:

5 رناد زكريا Dr. ahmad Dr. ahmad P a g e 1

Before we start. -This sheet was written according to section 2 s record and reviewed according to section 1 s record by Ruba Hussien with all thanks and I referred to last year sheets. - In this sheet, the topic about anemia will end and we ll start talking about polycythemia. - For you who want to go through the book this sheet will cover the pages 416-417 &425 & 447-448. In the previous lecture, we were talking about hemolytic anemia of intrinsic factor and we discussed the heredity types: 1-Membranopathies spherocytosis. 2-Hemoglobinopathies thalassemia and sickle cell disease. 3- Enzymopathies G6PD deficiency (it's our topic in this sheet). And the Acquired type, which is Paroxysmal nocturnal hemoglobinuria (it's our topic in this sheet as well). Enzymopathies G6PD deficiency G6PD is an enzyme which produces NADPH; NADPH will in turn reduce glutathione which will find reactive oxygen species and get rid of them. - So if we have G6PD deficiency, this cycle (shown in the figure) will break, making RBCs more prone to oxidative stress. - Cells that are more prone to oxidative stress are the old senescent RBCs; in other words, young RBCs are not affected as severely as old RBCs. - Remember that the half-life of an RBC is 120 days and with daily production and turnover of cells, old and new RBCs are found in the blood. P a g e 2

- G6PD deficiency is an X-linked disorder more common in males. - Many G6PD variants exist (over 400); those associated with disease are mainly two: 1- G6PD A- (common in African Americans). 2- G6PD Mediterranean (common in Middle East). - the Mediterranean is more severe than G6PD A-. *Hemolysis in G6PD deficiency is acute and episodic compared to hemolysis in spherocytosis where it is chronic. For example, if a patient who doesn t have chronic hemolysis and got exposed to an acute attack, he will suffer from hemolytic anemia; on the other hand, spherocytosis patients always have hemolysis even if it was presymptomatic or subclavian. **The acute attacks that cause acute episodic hemolysis in G6PD deficiency are: 1-Infections: most common cause. 2-Drugs: antimalarials, nitrofurantoin (old antibiotic for UTIs, especially in females). 3-Certain foods: fava beans; one of the least common causes. - Once the oxidative stress occurs, the old RBCs will undergo hemolysis. The acute episodic hemolysis will stop even when the patient takes the drug that causes the hemolysis or still has an infection. Why? Because the new RBCs have the ability to fight this oxidative stress more than the old ones, so once the old RBCs undergo hemolysis, the patient will come back to being normal. - After oxidation, the oxidized hemoglobin denatures and precipitates, forming intracellular inclusions called Heinz bodies. - Or the less severely damaged cells lose their deformability and suffer further injury when splenic phagocytes attempt to "pluck out" the Heinz bodies, creating so called bite cells. Remember: Heinz bodies are denatured hemoglobin molecules; when there is oxidative stress on the hemoglobin, the sulfhydryl groups within the amino acids will combine with each other causing precipitation (Heinz bodies). P a g e 3

This is the denatured globin Why are cells in the picture above cells (containing denatured globin) yellow compared to the normal color of RBCs? Because Heinz bodies are not seen by Wright Giemsa stain which we normally use (our routine stain that we use in every blood test; i.e. in staining peripheral blood and bone marrow); that s why we use a special stain known collectively as supravital stains, specifically crystal violet. ** Hemolysis in G6PD can be either intra- or extravascular depending on how much the oxidizing is or how strong the attack is. ** Since it s episodic and acute (rather than chronic) hemolysis, features related to chronic hemolysis (splenomegaly and gallbladder stones) are typically absent. Anemia s where splenomegaly and gallbladder stones are absent are: a. Aplastic anemia b. Sickle cell anemia c. G6PD deficiency Acquired: Paroxysmal nocturnal hemoglobinuria (PNH): - PNH is rare, is due to an acquired mutation (not an inherited disease), and is caused by a mutation on the protein found on RBCs that protect them from the complement system. P a g e 4

- Not all cells are affected; one clone in the body has this mutation. It's kind of similar to leukemia or any cancer; one clone of the disease is affected not the whole cells in the body, but here this condition is not neoplastic. **Mutations don t mean they are inherited. -To be inherited, the mutations must be germ cell mutations. - PNH results from acquired mutations in the phosphatidylinositol glycan complementation group A gene (PIGA), an enzyme that is essential for the synthesis of certain membrane-associated complement regulatory proteins -PIGA gene is present on the X chromosome. - A mutation in PIGA gene will result in decreased production of PIGA protein on the cellular membrane less CD55 and CD59 to counter complement proteins the cell will be more prone to complement fixation and hemolysis. - It is the only hemolytic anemia resulting from an acquired genetic mutation. Clinical manifestations 1- Low level chronic hemolytic anemia. 2- It's NOCTURNAL, why? Because the fixation of complement is enhanced by the slight decrease in blood ph that accompanies sleep, rendering cells more prone to hemolysis. 3- It has some association with aplastic anemia and thrombosis that s why the most encountered clinical scenario is when you suspect PNH in a young patient with anemia and thrombosis. 4- High incidence of bone marrow disorders like myelodysplastic syndrome and leukemia. ** The treatment of those patients will increase the risk of Neisseria infection, why? Because the treatment will fight the complement proteins, and complements specifically the last 5 proteins, which are called membrane attack complex (MAC) are really important in fighting Neisseria. If you inhibit these proteins, you will risk that the P a g e 5

patient might be affected by Neisseria. ** That was the last topic in anemia lectures. We will start with the new topic which is: Polycythemia Denotes an abnormally high red cell count, usually with a corresponding increase in the hemoglobin level. **In polycythemia, these two criteria usually go side by side, so whenever you hear polycythemia, it means high RBC count as well as elevated hemoglobin level. ** While in anemia, the decrease in hemoglobin level does not necessarily reflect low RBC Count. For example, in beta-thalassemia minor, there s a normal or increased RBC count (Erythrocytosis) associated with low hemoglobin level. ** Polycythemia may be absolute or relative. Relative Polycythemia - Occurs when there s a decrease in plasma volume with no change in the total RBC mass. * It results from dehydration, which occurs with diarrhea, vomiting or diuretic therapy. * Remember the case of the pregnant woman that has low blood count as a result of fluid retention that leads to an increase in RBC concentration, but she doesn t have anemia. The same concept is applied here. Absolute Polycythemia - In absolute polycythemia, the increase of RBC count is due to overproduction of RBCs in the bone marrow. * It s classified into primary and secondary absolute polycythemia. * It s described as primary when increased red blood cell mass results from autonomous proliferation of erythroid progenitors, independent of erythropoietin. While in secondary, this overproduction is induced by erythropoietin (no problem in the RBC). P a g e 6

In other words, -Primary polycythemia is associated with low erythropoietin levels -Secondary polycythemia is associated with elevated erythropoietin levels 1- Secondary absolute polycythemia: As we just mentioned, secondary absolute polycythemia results from excess stimulation of erythroid progenitors by erythropoietin. **But how does this occur and what is the relation between erythropoietin and oxygen? 1- Hypoxia is sensed by kidney cells. 2- Kidneys cells also have a transcription factor called HIF (hypoxia induced factor). 3- If hypoxia occurs, kidney cells will sense it and HIF factor will be stabilized; therefore, it will act as a transcriptional factor for many genes. One of them is the gene that codes for erythropoietin. 4- Finally, increased erythropoietin secretion by kidney cells would increase RBC production. ** Keep in mind, in high oxygen tension, HIF will be destroyed and thus inactivated. **Two types of hypoxia occur generalized hypoxia and localized hypoxia: a. Generalized hypoxia, like in smoking, High altitude and High affinity hemoglobins. Hemoglobin in these cases have high affinity to oxygen. P a g e 7

b. Localized hypoxia, like in renal artery stenosis and polycystic kidney disease ** Moreover, some tumors can secrete erythropoietin. Examples are Wilms tumor, Renal cell carcinoma, Cerebellar hemangioma, Hepatocellular carcinoma. 2- Primary absolute polycythemia: - Erythropoietin production will be low. The most common cause of primary absolute polycythemia is polycythemia vera. ** Polycythemia vera is characterized by increased marrow production of red cells, granulocytes, and platelets (panmyelosis), so when we take a bone marrow biopsy, we will see proliferation of all myeloid cells. - So, it s an acquired, clonal neoplasm of bone marrow stem cells (Chronic myeloproliferative neoplasm). ** PCV is Strongly associated with JAK2 mutation. Such mutation is present in more than 97% of PV cases: - It s strongly associated with PCV, but it s not specific as seen in 50% of cases of some other chronic myeloproliferative disorders, such as essential thrombocythemia and primary myelofibrosis. - The most common JAK2 mutation is a Valine-to-phenylalanine substitution at residue 617. ** At first, the patient will have mild splenomegaly which will then become more severe (as a result of the congestion of the spleen). Also, the bone marrow will become hypercellular. **Late in the disease course, bone marrow fibrosis and significant organomegaly is present, PCV carries a 2% risk for transforming to acute myeloid leukemia. - In myeloproliferative neoplasm, the spleen will be very large. ** Myeloproliferative neoplasms (we will talk about them in other lectures). They are four major neoplasms: P a g e 8

a. polycythemia vera b. primary myelofibrosis c. essential thrombocythemia d. chronic myelogenous leukemia Clinical Features: 1- Pruritis. 2- Headache; dizziness. 3- Hyperuricemia and gout. 4- Increased risk of both major bleeding and thrombotic episodes, why? Because of the high levels of RBCs that cause viscosity in the blood, bleeding would occur because of dysfunctional platelets, so what kills in PCV is the thrombosis not the neoplasm itself. Examples: a. Deep venous thrombosis. b. Stroke. c. Myocardial infarction. d. Bowel infarction. e. Budd-Chiari syndrome formation of a blood clot within the hepatic veins which may progress to cirrhosis. f. Epistaxis and bleeding gums. ** Major hemorrhage can occur in ~10% of the patients. ** Spent phase fibrosis and splenomegaly. **2% might transform to acute myeloid leukemia THROMBOSIS IS THE MAJOR RISK FOR MORTLAITY IN THESE PATIENTS. Treatment: Treatment is Phlebotomy and administration of JAK2 inhibitors: - If you have high count of RBCs, you have to donate them, as simple as that. -And recently, JAK2 inhibitors have been developed. P a g e 9

Criteria for PCV diagnosis according to WHO: Major criteria: 1. Haemoglobin >18.5 g/dl in men, 16.5 g/dl in women. Or other evidence of increased red cell volume. 2. Presence of JAK2 V617F or other functionally similar mutations such as JAK2 exon 12 mutation. Minor criteria: 1. Bone marrow biopsy showing hyper-cellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic and megakaryocytic proliferation. 2. Serum erythropoietin level below the reference range for normal. 3. Endogenous erythroid colony formation in vitro. (Not commonly used). - To diagnose PCV, you have to observe two major and minor criteria, or the first major criterion with two minor criteria. - The second major criterion is not sufficient, because JAK2 mutation is not specific for PCV. The Doctor s Questions: 1- Relative polycythemia occurs in the setting of: A. Wilms tumor B. Dehydration C. Renal cell carcinoma D. Polycythemia vera. E. Hypoxia P a g e 10

2- All of the following are examples of secondary absolute polycythemia, except: A. Smokers B. Renal artery stenosis C. Polycystic kidney D. Polycythemia vera E. High altitude 3- The risk of acute myeloid leukemia in polycythemia vera is: A. 2% B. 10% C. 30% D. 50% E. 70% 4- One of the following is a major criterion for PV: A. High hemoglobin B. Hypercellular bone marrow C. Low erythropoietin level D. High erythropoietin level E. Endogenous erythroid colony formation in vitro Answers: 1: B, 2: D, 3: A, 4: A "If you are not willing to risk the usual, you will have to settle for the ordinary." Sorry for any mistake P a g e 11

P a g e 12